The developing biotech sector in China

Richard Tadd Blog

Twenty years ago, China’s biotech industry was worth around $2.4bn. This year, its revenues are expected to exceed $1.2tn. That’s a remarkable achievement by any standards, and one that has understandably led to excitement among investors and industry professionals alike. How has it been achieved? How has the sector actually changed and what can we expect to see in the …

Real-world evidence regulations are on the way

Richard Tadd Blog

The last decade has seen increasing emphasis worldwide on the importance of well-regulated, real-world data collection and analysis as a follow-up to clinical trials for new medicines and medical devices. China is now taking steps to make regulatory changes of its own in this area. On 7 January 2020, the National Medical Products Association (NMPA) released a paper entitled Guiding …

Concerns over US clinical trials as it is revealed only 41% of results are reported in accordance with new laws

Richard Tadd Industry News

In January 2017, the US passed new regulations to ensure that all clinical trials would have their results reported within one year of primary completion – with hefty fines of up to US$10,000 a day for those who failed to comply with the new rules. Despite this, a recent study published by The Lancet found that almost six in 10 …

Why choose China for your next clinical trial?

Richard Tadd Blog

Are you looking for the right site for your next clinical trial? China may not have been on your radar, but with recent developments leading to a dramatic improvement in what it has to offer, it really should be. There are good reasons why more and more healthcare companies are choosing to work with Chinese CROs. Here are five you …